Clinical Trials Directory

Trials / Unknown

UnknownNCT05378009

Functional Dyspepsia Response to Relaxation Therapy and Physical Activity

Functional Dyspepsia Response to Relaxation Therapy Alone or Combined With Physical Activity

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
40 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Functional dyspepsia (FD) is a common gastrointestinal disease with high morbidity. Due to the drop in estrogen level, perimenopausal women with FD (PMFD) have an increase in emotional disorders such as depression, anxiety and sleep disorder.

Detailed description

the research will include 30 FD women during their perimenopause to receive for 8 weeks the following: relaxation therapy (Benson relaxation), physical exercise (on treadmill), and proton pump inhibitors. Also, the research will include another 30 FD women during their perimenopause to receive for 8 weeks the following: relaxation therapy (Benson relaxation) and proton pump inhibitors

Conditions

Interventions

TypeNameDescription
BEHAVIORALrelaxation and physical activityThis FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
BEHAVIORALrelaxationThis FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)

Timeline

Start date
2022-03-01
Primary completion
2022-06-15
Completion
2022-06-15
First posted
2022-05-17
Last updated
2022-05-17

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05378009. Inclusion in this directory is not an endorsement.